The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
|Videos|January 13, 2023
Dr. Ravi on unmet needs in PSMA-targeted paradigm
Author(s)Urology Times staff
Advertisement
Praful Ravi, MB, BChir, MRCP, discusses remaining needs and next steps with PSMA-targeted agents in prostate cancer.Ravi is a medical oncologisxt at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.
Advertisement
Related to this article
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement